Longevity Biotech Pitch Day — Boston
Longevity Biotech Pitch Day — Boston
Hosted by the Longevity Investor Network & Lifespan Research Institute
When: Sunday, October 4, 2026
Where: 650 E Kendall Street in Cambridge, Boston
About the Event
Join us for an exclusive evening in Boston as we showcase some of the most promising longevity startups shaping the future.
A handpicked group of companies will take the stage to share their vision, scientific breakthroughs, and growth potential in front of a curated audience of leading investors. This is a unique opportunity to get a first look at innovative ventures before they make their mark.
What to Expect
✨ Startup Pitches – Hear directly from founders building the next big thing in longevity.
🤝 Investor-Only Access – An intimate, invite-only setting designed for meaningful connections.
Agenda (times TBD)
1:30PM - 2:00PM: Registration / Networking
2:00PM - 2:10PM: Opening Remarks - Keith Comito
2:10PM - 2:30PM: Deciduous Therapeutics - Presentation
2:30PM - 2:50PM: MelliCell - Presentation
2:50PM - 3:10PM: Biochange - Presentation
3:10PM - 3:50PM: Break / Networking
3:50PM - 4:00PM: Lifespan Research Institute Advocacy - Keith Comito (Notes from our CEO & President)
4:00PM - 4:20PM: Maxwell Biosciences - Presentation
4:20PM - 4:40PM: Rejuvenation Technologies - Presentation
4:40PM - 5:00PM: Tolerance Bio - Presentation
5:00PM - 5:45PM: Break / Networking
Who's Pitching
Deciduous Therapeutics (https://www.deciduoustx.com/)
Deciduous Therapeutics is developing a novel immunotherapy designed to reverse established fibrosis by targeting a key driver of disease: a persistent, dysregulated immune response. Its lead clinical candidate, DCD-80, reprograms the immune system toward an anti-fibrotic state, attenuating established fibrosis and promoting the clearance of pathogenic senescent cells. DCD-80 has demonstrated compelling activity in gold-standard preclinical models and human ex vivo lung and endometrial tissue samples.
MelliCell (https://mellicell.com/)
MelliCell is developing an oral pill for autism and obesity by targeting a shared genetic switch at the root of multiple brain and metabolic diseases. Using an exclusive discovery engine, MelliCell discovered that this switch reverses obesity without muscle and bone loss similar to a keto diet. It also rescues intellectual disability and autism and controls genes like amyloid precursor that leads to early-onset Alzheimer's when elevated.
Biochange (https://biochange.life/)
BioChange is developing a new approach to regenerative medicine aimed at reawakening the body’s own ability to rebuild damaged and aging tissues. Its CellFoam™ platform recreates key features of the embryonic extracellular environment, providing a temporary 3D matrix that enables endogenous cells to communicate, organize and regenerate tissue—without adding stem cells or exogenous growth factors. The technology is already commercial in veterinary medicine, with tens of thousands of units used, and BioChange is now advancing human programs in periodontal and bone regeneration, skin, soft tissue and nerve repair. The company’s long-term vision is to transform medicine from managing tissue damage to enabling the body to regenerate it.
Maxwell Biosciences (https://maxwellbiosciences.com/)
Maxwell’s Claromers® are designed to mimic a fundamental mechanism of youthful innate immunity, reproducing the broad, protective functions of the human antimicrobial peptide LL-37 against bacterial, fungal and viral pathogens while supporting inflammatory control and tissue repair. Claromers are designed to restore the body's natural defenses so it can protect, repair and stay resilient the way it did when it was young. Claromers are not peptides. They are peptoids (small-molecule mimics of peptides) that are more stable, microbiome-safe and do not require refrigeration. Maxwell has completed a successful nonhuman primate study, and human trials are anticipated in 2027.
Rejuvenation Technologies (https://rejuvenationtech.com/)
Telomeres are protective DNA sequences at the ends of chromosomes that shorten with each cell division. When telomeres become critically short, cells stop dividing or die. Since cell division is essential for human life, short telomeres drive aging and disease by preventing stem cells from dividing to repair and regenerate damage from daily wear-and-tear, injury, and disease. Our breakthrough technology can safely lengthen telomeres in specific cells, potentially reversing cellular aging and preventing or treating diseases and conditions caused by short telomeres.
Tolerance Bio (https://www.tolerancebio.com/)
Tolerance Bio is the most clinically advanced longevity biotech company focused on the thymus. The thymus is the immune organ that trains T cells, and it plays a central role in healthspan. The thymus shrinks with age and under inflammatory stress. That decline raises vulnerability to infection, cancer and autoimmunity, and it weakens vaccine responses. Tolerance Bio aims to preserve, regenerate and modulate thymic function. The company is developing two phase 2 assets for thymus preservation and regeneration (anti-IL-33 and long-acting IL-7) in addition to iPSC and mRNA pre-clinical platforms to rebuild and modulate the thymus.
Event Details
📅 Date: Sunday, October 4, 2026
📍 Location: 650 E Kendall St, Cambridge, United States
🎟 Audience: Invite-only for investors
🤝 Investor Attendees:
Investors From: Longevity Investor Network, Age1, ContinuumHealthVC, DraperVC, LunarVentures, NFX, PioneerFundVC, PearVC, InsightPartners, XPrize, OutsidersFund, HCVC, BackedVC, LongevityTechFund, Longevity Vision Fund, BoxOne Ventures, SOS Ventures, Maximon, Juvenescence, 5AM Ventures, CambrianBio, AltosLabs, Canaan Partners, LongeVC, Methuselah Foundation, CurieBio, Centenarian Fund, Formic Ventures, Khosla Ventures, Prime Movers Lab, Life Science Angels, Emerging Longevity Ventures, HOF Capital, OrbiMed, IndieBio, Apollo Health Ventures, and more!
Register Your Interest
If you've received an invitation, please RSVP to confirm your spot. Space is limited.
Boston Longevity Week
https://www.bostonlongevityweek.com/
This event is part of the larger Boston Longevity Week: Eleven days bringing together the world's leading longevity researchers, investors, and entrepreneurs for landmark conferences, hackathons, and networking across Boston and beyond.
Skin Aging Symposium
This event is paired with Longevity Global's Skin Aging Symposium and will take place in the same venue directly before their event. See details here: https://luma.com/longevity-y6hb
Lifespan Research Institute ("LRI") is a 501(c)(3) nonprofit organization focused on the defeat of age-related disease and the extension of healthy human lifespan – through raising funds and awareness for scientific work addressing the root causes of the aging process, building a thriving ecosystem of mission aligned stakeholders which can be mobilized to strategic action, and spearheading relevant research projects directly. We work to identify, develop, and promote initiatives with outsized impact and the greatest potential to realize widespread access to regenerative medicine solutions targeting the disabilities and diseases of aging.
Lifespan.io Sponsors & Members of the Lifespan Alliance
We are deeply honored by and grateful for the support of our Lifespan Alliance members, whose contributions are integral to our mission to extend healthy human lifespan and overcome age-related disease. Join the Lifespan Alliance today: https://www.lifespan.io/get-involved/become-a-sponsor/
The Longevity Investor Network is an initiative of Lifespan Research Institute, a 501(c)(3) nonprofit formed through the merger of SENS Research Foundation and Lifespan.io.
As a 501(c)3 nonprofit, your support is vital to our mission at LRI — consider making a donation: https://www.lifespan.io/how-you-can-help/ to help us continue advancing longevity science and hosting impactful events like this one.
For more information on how to join the Longevity Investor Network, please reach out to javier@lifespan.io